Christopher Morrison
Cancer cells co-opt a variety of cellular pathways in their quest to propagate. Finding a switch that controls not just one of cancer’s weapons, but many at the same time,...
Pfizer's acquisition of Hsp90 specialist Serenex is the biggest direct validation by Big Pharma in this up and coming oncology space. Hsp90, sometimes termed a master regulator, has quickly emerged as an important cancer target and Pfizer's endorsement can only give the field a boost.
Christopher Morrison
Cancer cells co-opt a variety of cellular pathways in their quest to propagate. Finding a switch that controls not just one of cancer’s weapons, but many at the same time,...
Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.
From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.
Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.